Harmony Biosciences

$35.55 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Harmony Biosciences

Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders living with medical needs. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients living with narcolepsy. It enables to know narcolepsy and provides information and resources to individuals who live with, and healthcare professionals who treat patients with, this disorder. Narcolepsy is a chronic, debilitating neurologic disorder of sleep-wake state instability. The Company’s product, WAKIX (pitolisant), is a molecule with an action, designed to histamine signaling in the brain by binding to H3 receptors.

Stock Analysis

last close $34.09
1-mo return -17.8%
3-mo return 0.6%
avg daily vol. 301.36T
52-week high 48.5
52-week low 25.09
market cap. $2.2B
forward pe 19.4
annual div. -
roe 9.5%
ltg forecast -
dividend yield -
annual rev. $271M
inst own. 79.5%

Subscribe now for daily local and international financial news